Lilly clearly has an abundance of growth drivers -- and the list includes more than Mounjaro, Zepbound, and the six drugs discussed earlier. Cancer drug Verzenio, type 2 diabetes drug Jardiance, and autoimmune disease drug Taltz are all blockbusters with strong sales momentum.

Eli Lilly's experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to show promising clinical trial results for additional health benefits, the company said.

Biopharmaceutical start-up BioAge Labs is developing a weight loss drug for older adults known as azelaprag, which is intended to be taken orally along with other weight loss drugs. According to the company which partners with Eli Lilly,

In fact, demand has been so high that it's been surpassing supply, forcing Lilly and rival Novo Nordisk to invest in additional manufacturing capacity. Recently, Lilly made a new move that could solve this supply issue -- the biggest problem facing these drug makers -- and boost Lilly's already strong earnings.